Class: Fluoroquinolone Antibiotic
Dosage Forms. Tablet: 400 mg
Common FDA Label Indication, Dosing, and Titration.
1. Acute infective exacerbation of chronic obstructive pulmonary disease: 400 mg po daily × 5 d
2. Bacterial sinusitis, acute: 400 mg po daily × 10 d
3. Community acquired pneumonia: 400 mg po daily × 7-14 d
4. Infection of skin and/or subcutaneous tissue: 400 mg po daily × 7-21 d
1. Tuberculosis: 400 mg po daily × 6 mo
MOA. Moxifloxacin is a fluoroquinolone that inhibits bacterial topoisomerase II and IV. It is highly active against aerobic, Gram-negative bacilli, especially Enterobacteriaceae. It has poor activity against streptococci and anaerobes.
Drug Characteristics: Moxifloxacin
Medication Safety Issues: Moxifloxacin
Drug Interactions: Moxifloxacin
Adverse Reactions: Moxifloxacin
Efficacy Monitoring Parameters. Resolution of signs and symptoms of infection.
Toxicity Monitoring Parameters. Seek medical attention if decreased urination, yellowing of eyes, blistering skin rash or extreme fatigue, unusual bruising or bleeding, shortness of breath or chest pain, tendon pain, unusual thoughts, or numbness or tingling in the arms or legs. Baseline renal function tests.
Key Patient Counseling Points. Seek medical attention if rash develops. Complete full course of therapy. Symptoms should improve within 2-3 d; if they worsen, seek follow-up with healthcare practitioner. If tendon pain develops, discontinue use and seek medical attention. Patients over the age of 65 y and on concurrent steroids are at increased risk. You may take this medicine with or without food. Do not take this medicine with milk, yogurt, or other dairy products or calcium-fortified products (some juices and breads). If using antacids, sucralfate, or mineral supplements and multivitamins with calcium, iron, or zinc, take ciprofloxacin at least 2 h before or 6 h after these medicines.
Clinical Pearls. Moxifloxacin is not approved in children younger than 18 y of age. Oral and IV dosing is interchangeable.